Conditions: Ovarian Cancer Primary Peritoneal Cancer Fallopian Tube Cancer
Keywords: bevacizumab paclitaxel carboplatin ovarian cancer fallopian tube primary peritoneal
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 9
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine the maximum tolerated dose (MTD) of intravenous weekly paclitaxel given with intravenous carboplatin and bevacizumab in patients with epithelial ovarian, primary peritoneal, or fallopian tube carcinoma that are to receive neoadjuvant chemotherapy (prior to surgical cytoreduction). Patients will then undergo surgery which will allow an objective measure of response to the above regimen as well as assessment of surgical outcomes.

Detailed description:
Phase I study proposed to evaluate:

* Tolerability of IV regimen carboplatin, paclitaxel and bevacizumab in the neoadjuvant setting prior to surgery.
* Safety/Toxicity of IV regimen in this patient population
* Treatment is Carboplatin area under the concentration curve (AUC) 5, Bevacizumab 15mg/m2, and starting dose of paclitaxel of 60mg/m2 and will be escalated in intervals of 10mg/m2 to a maximum dose of 80mg/m2.
* Patients will receive cycles 1-3 of carboplatin, bevacizumab, and paclitaxel and then cycle 4 will be carboplatin and paclitaxel followed by surgical intervention within 6 weeks of cycle 4.
* Post surgical treatment per physician discretion

Arms:
arm 1: AUC 5.0 or 6.0 arm 2: 15 mg/kg arm 3: 60-80 mg/m2

Interventions: intervention 1: carboplatin intervention 2: Bevacizumab intervention 3: Paclitaxel
Intervention descriptions: intervention 1: Carboplatin AUC 5.0 or 6.0 will be administered on day 1 during cycle 1-3. Treatment cycle consists of 21 days duration. intervention 2: Bevacizumab 15 mg/kg administered on Day 1 during cycle 1-3. Treatment cycle consists of 21 days duration. intervention 3: 60-80 mg/m2 administered on Day 1, 8 \& 15 during cycle 1-3. Treatment cycle consists of 21 days duration.

Protocol document: